- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Business description – A detailed description of the company’s operations and business divisions.
Corporate strategy – GlobalData’s summarization of the company’s business strategy.
SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history – Progression of key events associated with the company.
Major products and services – A list of major products, services and brands of the company.
Key competitors – A list of key competitors to the company.
Key employees – A list of the key executives of the company.
Executive biographies – A brief summary of the executives’ employment history.
Key operational heads – A list of personnel heading key departments/functions.
Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Emcure Pharmaceuticals Ltd (Emcure) develops, manufactures, and commercializes pharmaceutical products worldwide. The company develops and manufactures branded generic products. It also manufactures active pharmaceutical ingredients (APIs) primarily for use in the manufacturing of pharmaceutical products. Emcure has a presence in all major therapeutic areas, which comprises cardiology, pain and analgesics, HIV, gynecology, blood-related, anti-infective, nephrology, diabetes, and cancer among others as well as vitamins, minerals, and nutrients products. It has an operational presence in Brazil, Dubai, South Africa, Singapore, and Nigeria. The company has branch offices in Russia and Morocco. Emcure is headquartered in Pune, Maharashtra, India.
Mar 17,2022: 35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries
Reasons to Buy
Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note:Some sections may be missing if data is unavailable for the company.
Emcure Pharmaceuticals Ltd - Major Products and Services
Emcure Pharmaceuticals Ltd - History
Emcure Pharmaceuticals Ltd - Company Statement
Emcure Pharmaceuticals Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Emcure Pharmaceuticals Ltd - Business Description
R&D Overview
Emcure Pharmaceuticals Ltd - Corporate Strategy
Emcure Pharmaceuticals Ltd - SWOT Analysis
SWOT Analysis - Overview
Emcure Pharmaceuticals Ltd - Strengths
Emcure Pharmaceuticals Ltd - Weaknesses
Emcure Pharmaceuticals Ltd - Opportunities
Emcure Pharmaceuticals Ltd - Threats
Emcure Pharmaceuticals Ltd - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Emcure Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Emcure Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Emcure Pharmaceuticals Ltd, Recent Deals Summary
Section 4 – Company’s Recent Developments
Mar 17, 2022: 35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries